These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32893006)

  • 1. Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer.
    Minko T
    Trends Pharmacol Sci; 2020 Oct; 41(10):684-686. PubMed ID: 32893006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoformulation of PROteolysis TArgeting Chimera targeting 'undruggable'
    Saraswat A; Patki M; Fu Y; Barot S; Dukhande VV; Patel K
    Nanomedicine (Lond); 2020 Aug; 15(18):1761-1777. PubMed ID: 32698663
    [No Abstract]   [Full Text] [Related]  

  • 3. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
    Lu J; Qian Y; Altieri M; Dong H; Wang J; Raina K; Hines J; Winkler JD; Crew AP; Coleman K; Crews CM
    Chem Biol; 2015 Jun; 22(6):755-63. PubMed ID: 26051217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera.
    Vartak R; Saraswat A; Yang Y; Chen ZS; Patel K
    Pharm Res; 2022 Nov; 39(11):2745-2759. PubMed ID: 35146591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
    Saenz DT; Fiskus W; Qian Y; Manshouri T; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Mill CP; Sun B; Qiu P; Kadia TM; Pemmaraju N; DiNardo C; Kim MS; Nowak AJ; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
    Leukemia; 2017 Sep; 31(9):1951-1961. PubMed ID: 28042144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
    Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
    J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.
    He L; Chen C; Gao G; Xu K; Ma Z
    Aging (Albany NY); 2020 Mar; 12(5):4547-4557. PubMed ID: 32163373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
    Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
    Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
    Wu S; Jiang Y; Hong Y; Chu X; Zhang Z; Tao Y; Fan Z; Bai Z; Li X; Chen Y; Li Z; Ding X; Lv H; Du X; Lim SL; Zhang Y; Huang S; Lu J; Pan J; Hu S
    Cancer Cell Int; 2021 Apr; 21(1):230. PubMed ID: 33888130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy.
    He Y; Ju Y; Hu Y; Wang B; Che S; Jian Y; Zhuo W; Fu X; Cheng Y; Zheng S; Huang N; Qian Z; Liu J; Zhou P; Gao X
    J Control Release; 2023 Feb; 354():155-166. PubMed ID: 36538950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARV-825 Demonstrates Antitumor Activity in Gastric Cancer
    Liao X; Qian X; Zhang Z; Tao Y; Li Z; Zhang Q; Liang H; Li X; Xie Y; Zhuo R; Chen Y; Jiang Y; Cao H; Niu J; Xue C; Ni J; Pan J; Cui D
    Front Oncol; 2021; 11():753119. PubMed ID: 34733788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.
    Nie X; Zhao Y; Tang H; Zhang Z; Liao J; Almodovar-Rivera CM; Sundaresan R; Xie H; Guo L; Wang B; Guan H; Xing Y; Tang W
    Chembiochem; 2024 Feb; 25(4):e202300685. PubMed ID: 38116854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
    Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
    Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation.
    Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ
    J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy.
    He Q; Zhou L; Yu D; Zhu R; Chen Y; Song M; Liu X; Liao Y; Ding T; Fan W; Yu W
    J Med Chem; 2023 Aug; 66(15):10458-10472. PubMed ID: 37279091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
    Ohoka N
    Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.
    Sun B; Fiskus W; Qian Y; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Saenz DT; Mill CP; Nowak AJ; Jain N; Zhang L; Wang M; Khoury JD; Coarfa C; Crews CM; Bhalla KN
    Leukemia; 2018 Feb; 32(2):343-352. PubMed ID: 28663582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
    Yang C; Yang Y; Li Y; Ni Q; Li J
    J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ARV-825 Showed Antitumor Activity against BRD4-NUT Fusion Protein by Targeting the BRD4.
    Yang L; Jing Y; Xia X; Yin X
    J Oncol; 2023; 2023():9904143. PubMed ID: 38130463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation.
    Rathod D; Fu Y; Patel K
    Eur J Pharm Sci; 2019 Oct; 138():105039. PubMed ID: 31394259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.